1-158662793-G-T
Position:
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BA1
The NM_003126.4(SPTA1):c.2373C>A(p.Asp791Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00281 in 1,614,022 control chromosomes in the GnomAD database, including 97 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.015 ( 52 hom., cov: 32)
Exomes 𝑓: 0.0016 ( 45 hom. )
Consequence
SPTA1
NM_003126.4 missense
NM_003126.4 missense
Scores
5
13
Clinical Significance
Conservation
PhyloP100: 1.99
Genes affected
SPTA1 (HGNC:11272): (spectrin alpha, erythrocytic 1) This gene encodes a member of a family of molecular scaffold proteins that link the plasma membrane to the actin cytoskeleton and functions in the determination of cell shape, arrangement of transmembrane proteins, and organization of organelles. The encoded protein is primarily composed of 22 spectrin repeats which are involved in dimer formation. It forms a component of the erythrocyte plasma membrane. Mutations in this gene result in a variety of hereditary red blood cell disorders, including elliptocytosis-2, pyropoikilocytosis, and spherocytosis, type 3. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -13 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0041577816).
BP6
Variant 1-158662793-G-T is Benign according to our data. Variant chr1-158662793-G-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 12859.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=4, Benign=2, Likely_pathogenic=1}. Variant chr1-158662793-G-T is described in Lovd as [Pathogenic].
BA1
GnomAdExome4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.053 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SPTA1 | NM_003126.4 | c.2373C>A | p.Asp791Glu | missense_variant | 17/52 | ENST00000643759.2 | NP_003117.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SPTA1 | ENST00000643759.2 | c.2373C>A | p.Asp791Glu | missense_variant | 17/52 | NM_003126.4 | ENSP00000495214.1 |
Frequencies
GnomAD3 genomes AF: 0.0144 AC: 2192AN: 152140Hom.: 51 Cov.: 32
GnomAD3 genomes
AF:
AC:
2192
AN:
152140
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00362 AC: 904AN: 249438Hom.: 23 AF XY: 0.00265 AC XY: 359AN XY: 135332
GnomAD3 exomes
AF:
AC:
904
AN:
249438
Hom.:
AF XY:
AC XY:
359
AN XY:
135332
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00160 AC: 2335AN: 1461764Hom.: 45 Cov.: 31 AF XY: 0.00138 AC XY: 1001AN XY: 727184
GnomAD4 exome
AF:
AC:
2335
AN:
1461764
Hom.:
Cov.:
31
AF XY:
AC XY:
1001
AN XY:
727184
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0145 AC: 2208AN: 152258Hom.: 52 Cov.: 32 AF XY: 0.0144 AC XY: 1070AN XY: 74444
GnomAD4 genome
AF:
AC:
2208
AN:
152258
Hom.:
Cov.:
32
AF XY:
AC XY:
1070
AN XY:
74444
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
3
ALSPAC
AF:
AC:
3
ESP6500AA
AF:
AC:
186
ESP6500EA
AF:
AC:
3
ExAC
AF:
AC:
521
Asia WGS
AF:
AC:
23
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:2Benign:6
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:1Benign:2
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 27, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jul 01, 2024 | Spectrin Jendouba is a missense alteration in alpha spectrin that has long been associated with elliptocytosis. In our opinion, Spectrin Jendouba erroneously is classified as benign due to automated filters and strict cut-offs to classify alterations with MAF >5% as benign because this alteration has a high MAF in some subpopulations in population databases. For hereditary elliptocytosis a higher than 5% MAF may be acceptable, particularly in persons with ancestry from the malaria belt. Because it usually causes little other clinical manifestations, HE is under diagnosed, but is estimated to be 1 in 2000 – 1 in 4000 worldwide and up to 1 in 50 in African/African American sub-populations (UpToDate). Therefore, we suggest an exception from BA1 for SPTA1 gene based on the likely enrichment of disorder-causing alleles in ancestral populations where malaria is endemic. There is heterozygous advantage, particularly in genes affecting RBCs (Lelliott 2015 PMID 26215182), similar to what is suggested by the Hemoglobinopathy Variant Curation Expert Panel (Kountouris 2022 PMID 34510646). In regards to the specific pathogenicity of Spectrin Jendouba, there are numerous reports in the literature of its association with elliptocytosis and other RBC membranopathies if co-inherited with pathogenic alterations (Niss 2016 PMID 27667160, Alloisio 1992 PMID: 1638030, Kim 2021 PMID 33556202, Van Vuren 2019 PMID: 31723846). Most hereditary elliptocytosis variants are found in the C-terminal of helices 3. (Alloisio 1992 PMID: 1638030). This alteration occurs in helix 3, distant from the spectrin head-to-head self-association site resulting in a mild defect in spectrin dimer self-association. Our internal data including peripheral blood smear review showed all instances of Spectrin Jendouba presented with some red blood cell abnormality (mainly elliptocytes, however, when found with alphaLELY, also poikilocytes, spherocytes). Overall, based on the available evidence, we classify this variant as likely pathogenic. - |
Elliptocytosis 2 Pathogenic:1Benign:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 1992 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jan 05, 2024 | The p.Asp791Glu variant in SPTA1 is classified as likely benign because it has been identified in 4.97% (2060/41414) of African chromosomes by gnomAD (http://gnomad.broadinstitute.org, v.3.1.2), including 51 homozygotes. In addition, computational prediction tools predict that this variant does not impact the protein. ACMG/AMP Criteria applied: BS1, BP4. - |
Hereditary spherocytosis type 3 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Pyropoikilocytosis, hereditary Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;M
PrimateAI
Benign
T
PROVEAN
Benign
N;.
REVEL
Benign
Sift
Benign
T;.
Sift4G
Benign
T;.
Polyphen
P;P
Vest4
MutPred
Gain of disorder (P = 0.1156);Gain of disorder (P = 0.1156);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at